CN1385214A - 奥美拉唑钠粉针剂的专用溶剂 - Google Patents
奥美拉唑钠粉针剂的专用溶剂 Download PDFInfo
- Publication number
- CN1385214A CN1385214A CN 02113079 CN02113079A CN1385214A CN 1385214 A CN1385214 A CN 1385214A CN 02113079 CN02113079 CN 02113079 CN 02113079 A CN02113079 A CN 02113079A CN 1385214 A CN1385214 A CN 1385214A
- Authority
- CN
- China
- Prior art keywords
- injection
- sodium
- water
- omeprazole
- omeprazole sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 39
- 239000007924 injection Substances 0.000 title claims abstract description 39
- 229940063517 omeprazole sodium Drugs 0.000 title claims abstract description 38
- KNVABRFVZVESIL-UHFFFAOYSA-N sodium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound [Na+].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C KNVABRFVZVESIL-UHFFFAOYSA-N 0.000 title claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000002904 solvent Substances 0.000 claims abstract description 34
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 10
- 229910017053 inorganic salt Inorganic materials 0.000 claims abstract description 10
- 239000008156 Ringer's lactate solution Substances 0.000 claims abstract description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 5
- 239000001110 calcium chloride Substances 0.000 claims abstract description 5
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 5
- 235000011148 calcium chloride Nutrition 0.000 claims abstract description 5
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims abstract description 5
- 239000001527 calcium lactate Substances 0.000 claims abstract description 5
- 235000011086 calcium lactate Nutrition 0.000 claims abstract description 5
- 229960002401 calcium lactate Drugs 0.000 claims abstract description 5
- 239000011780 sodium chloride Substances 0.000 claims abstract description 5
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims abstract description 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims abstract description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims abstract description 3
- 239000008215 water for injection Substances 0.000 claims description 32
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 19
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 238000009826 distribution Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 abstract 1
- RTWNYYOXLSILQN-UHFFFAOYSA-N methanediamine Chemical compound NCN RTWNYYOXLSILQN-UHFFFAOYSA-N 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 238000005303 weighing Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 238000010253 intravenous injection Methods 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- 238000005374 membrane filtration Methods 0.000 description 6
- 239000004576 sand Substances 0.000 description 6
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229940093181 glucose injection Drugs 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 229960000381 omeprazole Drugs 0.000 description 5
- 206010018910 Haemolysis Diseases 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 239000008354 sodium chloride injection Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 3
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明奥美拉唑钠粉针剂的专用溶剂涉及的是一种专供溶解奥美拉唑钠粉针剂的专用溶剂及其制备方法。奥美拉唑钠针剂的专用溶剂由无机盐或有机盐、乙二胺四乙酸二钠、注射用水配制而成,其中各组分重量百分配比为:无机盐或有机盐0.9%～15%、乙二胺四乙酸二钠0.01%～0.1%、注射用水余量;无机盐采用氯化钠、碳酸氢钠、磷酸二氢钠、氯化钙中的一种,有机盐采用乳酸钠溶液、乳酸钙中的一种。
Description
技术领域
本发明奥美拉唑钠粉针剂的专用溶剂涉及的是一种专供溶解奥美拉唑钠粉针剂的专用溶剂及其制备方法。
背景技术
奥美拉唑钠粉针剂国内外有两种类型的制剂，一种是专供静脉推注的奥美拉唑钠粉针剂，配有一种含聚乙二醇(PEG400)的非水溶剂，供溶解奥美拉唑钠粉针剂；另一种是供静脉推注的奥美拉唑钠粉针剂无专用溶剂，使用前0.9％氯化钠注射液稀释最合适。前者供静脉推注的奥美拉唑钠的专用溶剂，因含高分子物质聚乙二醇(PEG400)，PEG400易产生溶血，刺激性。如不用PEG400，用普通的注射用水溶解奥美拉唑钠不完全。后者供静脉滴注的奥美拉唑钠亦能用5％葡萄糖注射液稀释，如果用5％葡萄糖注射液稀释易产生主药沉淀或使主药降解。因此寻找一种既能供静脉推注又能供静脉滴注的水性专用溶剂非常必要。
发明内容
本发明针对上述不足之处提供一种奥美拉唑钠粉针剂的专用溶剂，是一种水性专用溶剂，溶解后的奥美拉唑钠粉针剂既能供静脉滴注又能供静脉推注。
奥美拉唑钠粉针剂的专用溶剂是采取以下方案实现的：奥美拉唑钠粉针剂专用溶剂由无机盐或有机盐、乙二胺四乙酸二钠(EDTA)、注射用水配制而成，其中各组分重量百分配比为：
无机盐或有机盐 0.9％～15％
乙二胺四乙酸二钠(EDTA) 0.01％～0.1％
注射用水 余量
组分中的无机盐或有机盐用于调节溶剂等渗。乙二胺四乙酸二钠EDTA为络合剂，是一种被溶解物的稳定剂，对溶解的奥美拉唑钠起稳定作用，使溶解物奥美拉唑钠溶解后不再出现析出。
上述组分中的无机盐可采用氯化钠、碳酸氢钠、磷酸二氢钠、氯化钙中的一种。
上述组分中的有机盐可采用乳酸钠溶液、乳酸钙中的一种。
奥美拉唑钠粉针剂的专用溶剂制备方法。
按上述组分配比称量原料无机盐或有机盐、乙二胺四乙酸二钠，注射用水备用；取无机盐或有机盐、乙二胺四乙酸二钠加入上述称量80％左右注射用水，搅拌后全部溶解，用1mol/L盐酸溶液或1mol/L氢氧化钠溶液调节pH值3.8～4.5，加注射用水稀释至全量，即加入剩余注射用水，按每瓶10ml分装于10ml安额瓶中，封口，经100℃左右，60分钟流通蒸汽灭菌，检验合格，即制成成品。
本发明与现有技术相比具有的有益效果优点：
本发明解决了临床上一直无一种水性溶剂溶解奥美拉唑钠粉针剂。现有溶解奥美拉唑钠粉针剂的专用溶剂含有高分子物质聚乙二醇400，该专用溶剂溶解奥美拉唑钠粉针剂后，仅能供静脉推注，不能供静脉滴注，加入0.9％氯化钠注射液或5％葡萄糖注射液后，奥美拉唑钠溶液马上会变色，奥美拉唑降解，而且PEG400具有易产生溶血、血管刺激的现象，因此，这种专用溶剂处方不科学、不先进，使用范围狭窄。如果不用专用溶剂溶解奥美拉唑钠粉针剂，而直接使用0.9％氯化钠注射液溶解，除奥美拉唑钠溶解不完全以外，更易生产微晶现象，直接使用5％葡萄糖注射液稀释，除了奥美拉唑钠溶解不完全以外，更易使奥美拉唑分解，药物溶液变色。因此发明一种水性专用溶剂，不仅能完全溶解奥美拉唑钠，还能同时用0.9％氯化钠注射液或5％葡萄糖注射液稀释，而且克服了含有PEG400专用溶剂易产生溶血、血管刺激现象的缺点。本发明水性专用溶剂不仅能供静脉滴注，还能供静脉推注。
具体实施方式：实施例1：制备奥美拉唑钠粉针剂的专用溶剂100kg
按组分配比称量原料氯化钠0.9kg(重量配比0.9％)乙二胺四乙酸二钠0.01kg(重量配比0.01％)、注射用水99.09kg(重量配比99.09％)备用；取称量好的上述氯化钠0.9kg及乙二胺四乙酸二钠EDTA 0.01kg加入79.27kg注射用水中，占上述称量的注射用水总量80％，搅拌至全部溶解，用1mol/L盐酸钠溶液或1mol/L氢氧化钠溶液调节pH值至3.8～4.5，加注射用水19.82kg(上述称量注射用水20％)稀释至全量，经砂棒、滤球及0.22μm膜过滤后，按每瓶10ml分装于10ml安额瓶中，封口，经100℃、60分钟流通蒸汽灭菌，检验合格，即制得成品。实施例2：制备奥美拉唑钠粉针剂的专用溶剂100kg
按组分配比称量原料氯化钙5kg(重量配比5％)乙二胺四乙酸二钠EDTA0.06kg(重量配比0.06％)、注射用水94.94kg(重量配比99.94％)备用；取称量好的上述氯化钙5kg及乙二胺四乙酸二钠EDTA 0.06kg加入75.95kg注射用水(占上述称量的注射用水总量80％)中，搅拌至全部溶解，用1mol/L盐酸溶液或1mol/L氢氧化钠溶液调节pH值至3.8～4.5，加注射用水18.99kg(上述称量注射用水20％)稀释至全量，经砂棒、滤球及0.22μm膜过滤后，按每瓶10ml分装于10ml安额瓶中，封口，经100℃、60分钟流通蒸汽灭菌，检验合格，即制得成品。实施例3：制备奥美拉唑钠粉针剂的专用溶剂100kg
按组分配比称量原料碳酸氢钠15kg(重量配比15％)乙二胺四乙酸二钠0.1kg(重量配比0.1％)、注射用水84.9kg(重量配比84.9％)备用；取称量好的上述酸氢钠15kg及乙二胺四乙酸二钠EDTA 0.1kg加入67.92kg注射用水(占上述称量的注射用水总量80％)中，搅拌至全部溶解，用1mol/L盐酸溶液或1mol/L氢氧化钠溶液调节pH值至3.8～4.5，加注射用水16.98kg(上述称量注射用水20％)稀释至全量，经砂棒、滤球及0.22μm膜过滤后，按每瓶10ml分装于10ml安额瓶中，封口，经100℃、60分钟流通蒸汽灭菌，检验合格，即制得成品。实施例4：制备奥美拉唑钠粉针剂的专用溶剂100kg
按组分配比称量原料乳酸钙0.9kg(重量配比0.9％)、乙二胺四乙酸二钠0.01kg(重量配比0.01％)、注射用水99.09kg(重量配比99.09％)备用；取称量好的上述乳酸钙0.9kg及乙二胺四乙酸二钠EDTA 0.01kg加入79.27kg注射用水(占上述称量的注射用水总量80％)中，搅拌至全部溶解，用1mol/L盐酸溶液或1mol/L氢氧化钠溶液调节pH值至3.8～4.5，加注射用水19.82kg(上述称量注射用水20％)稀释至全量，经砂棒、滤球及0.22μm膜过滤后，按每瓶10ml分装于10ml安额瓶中，封口，经100℃、60分钟流通蒸汽灭菌，检验合格，即制得成品。实施例5：制备奥美拉唑钠粉针剂的专用溶剂100kg
按组分配比称量原料40％乳酸钠溶液37.5kg(乳酸钠重量配比15％)、乙二胺四乙酸二钠0.1kg(重量配比0.1％)、注射用水62.40kg(重量配比62.40％)备用；取称量好的上述40％乳酸钠溶液37.5kg及乙二胺四乙酸二钠0.1kg加入50kg注射用水(占上述称量的注射用水总量80％)中，搅拌至全部溶解，用1mol/L盐酸溶液或1mol/L氢氧化钠溶液调节pH值至3.8～4.5，加注射用水12.40kg(上述称量注射用水20％)稀释至全量，经砂棒、滤球及0.22μm膜过滤后，按每瓶10ml分装于10ml安额瓶中，封口，经100℃、60分钟流通蒸汽灭菌，检验合格，即制得成品。实施例6：制备奥美拉唑钠粉针剂的专用溶剂100kg
按组分配比称量原料40％乳酸钠溶液20kg(乳酸钠重量配比8％)、乙二胺四乙酸二钠0.08kg(重量配比0.08％)、注射用水79.92kg(重量配比79.92％)备用；取称量好的上述40％乳酸钠溶液20kg及乙二胺四乙酸二钠0.08kg加入63.94kg注射用水(占上述称量的注射用水总量80％)中，搅拌至全部溶解，用1mol/L盐酸溶液或1mol/L氢氧化钠溶液调节pH值至3.8～4.5，加注射用水15.98kg(上述称量注射用水20％)稀释至全量，经砂棒、滤球及0.22μm膜过滤后，按每瓶10ml分装于10ml安额瓶中，封口，经100℃、60分钟流通蒸汽灭菌，检验合格，即制得成品。
本发明制备的奥美拉唑钠粉针剂的专用溶剂配制奥美拉唑注射液
(1支注射用奥美拉唑加1支专用溶剂)溶血试验结果：无溶血及红细胞凝集作用。
本发明制备的奥美拉唑钠粉针剂的专用溶剂配制奥美拉唑注射液经动物静脉血管多次给药试验结果：无血管刺激作用。
Claims (3)
1、一种奥美拉唑钠粉针剂的专用溶剂，其特征在于其溶剂由无机盐或有机盐、乙二胺四乙酸二钠、注射用水配制而成，其中各组分重量百分配比为：无机盐或有机盐 0.9％～15％
乙二胺四乙酸二钠 0.01％～0.1％
注射用水 余量
2、根据权利要求1所述的奥美拉唑钠粉针剂的专用溶剂，其特征在于无机盐采用氯化钠、碳酸氢钠、磷酸二氢钠、氯化钙中的一种。
3、根据权利要求1所述的奥美拉唑钠粉针剂的专用溶剂，其特征在于有机盐采用乳酸钠溶液、乳酸钙中的一种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021130795A CN1194761C (zh) | 2002-05-31 | 2002-05-31 | 奥美拉唑钠粉针剂的专用溶剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021130795A CN1194761C (zh) | 2002-05-31 | 2002-05-31 | 奥美拉唑钠粉针剂的专用溶剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1385214A true CN1385214A (zh) | 2002-12-18 |
| CN1194761C CN1194761C (zh) | 2005-03-30 |
Family
ID=4742424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021130795A Expired - Lifetime CN1194761C (zh) | 2002-05-31 | 2002-05-31 | 奥美拉唑钠粉针剂的专用溶剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1194761C (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103054863A (zh) * | 2012-12-28 | 2013-04-24 | 海南锦瑞制药股份有限公司 | 一种奥美拉唑钠的药物组合物及其制备方法 |
-
2002
- 2002-05-31 CN CNB021130795A patent/CN1194761C/zh not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103054863A (zh) * | 2012-12-28 | 2013-04-24 | 海南锦瑞制药股份有限公司 | 一种奥美拉唑钠的药物组合物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1194761C (zh) | 2005-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104031170B (zh) | 一种人静脉注射用右旋糖酐铁原料及其制备方法 | |
| CN101455631B (zh) | 环磷腺苷葡胺注射液及其制备工艺 | |
| CN108997716A (zh) | 一种环保纳米银抑菌复合物 | |
| CN101120768A (zh) | 一种液体甜味剂及其制备方法 | |
| CN103880136B (zh) | 环保型镁离子改性蒙脱石自来水絮凝剂及其应用 | |
| CN1194761C (zh) | 奥美拉唑钠粉针剂的专用溶剂 | |
| CN102352047B (zh) | 一种甲壳素球的制备方法 | |
| CN103110574A (zh) | 一种替硝唑注射液制剂及其制备方法 | |
| CN102993037A (zh) | 一种l-鸟氨酸苯乙酸盐的制备方法 | |
| CN104611786A (zh) | 一种持续抑菌炭纤维敷料制备方法 | |
| CN105153458A (zh) | 一种低水溶性白芨多糖多孔膜的制备方法 | |
| CN105168120B (zh) | 一种钙化羧化壳聚糖纳米溶液及其制备方法 | |
| CN103571662A (zh) | 一种配制管道清的新工艺 | |
| CN1120044C (zh) | 脱色用纤维素纤维离子交换吸附剂的制备方法 | |
| CN101863541A (zh) | 环保型自来水絮凝剂 | |
| CN101362660A (zh) | 一种具有增效剂的氮肥及其生产方法 | |
| CN100542981C (zh) | 高浓缩循环水阻垢软水剂及水处理方法 | |
| CN1164723C (zh) | 一种皂角流浸膏 | |
| CN103816543A (zh) | 一种磷酸盐缓冲溶液的配置方法 | |
| CN102614214A (zh) | 一种复合聚维酮碘片剂及其制备方法 | |
| CN102172352B (zh) | 一种供注射用的硫辛酸组合物及其制备方法 | |
| CN108836940A (zh) | 注射用奥美拉唑专用溶剂及其制备方法 | |
| CN110200905A (zh) | 一种盐酸氨溴索组合物及其注射液与应用 | |
| CN103211757A (zh) | 一种依达拉奉注射液及其配制方法 | |
| CN116730516B (zh) | 低磷阻垢缓蚀剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Jiangsu Aosaikang Pharmaceutical Co., Ltd. Assignor: Chen Qingcai Contract fulfillment period: 2005.7.18 to 2022.5.30 Contract record no.: 2008320000671 Denomination of invention: Dissolvent specially for omeprazole sodium injection Granted publication date: 20050330 License type: Exclusive license Record date: 20081009 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2005.7.18 TO 2022.5.30; CHANGE OF CONTRACT Name of requester: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. Effective date: 20081009 |
|
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHEN QINGCAI Effective date: 20110315 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210029 TOWER C, 20/F, HANZHONG NEW CITY, NO. 1, HANZHONGMEN AVENUE, NANJING CITY, JIANGSU PROVINCE TO: 211112 NO. 699, KEJIAN ROAD, JIANGNING SCIENCE PARK, NANJING CITY, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110315 Address after: 211112 Jiangsu Province, Nanjing City, Jiangning Science Park Road No. 699 Patentee after: Jiangsu Aosaikang Pharmaceutical Co., Ltd. Address before: 210029, C, 20 floor, Hanzhoung Xincheng, 1 Hanzhoung Avenue, Jiangsu, Nanjing Patentee before: Chen Qingcai |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 211112 Jiangsu Province, Nanjing City, Jiangning Science Park Road No. 699 Patentee after: Jiangsu Aosaikang Pharmaceutical Co., Ltd. Address before: 211112 Jiangsu Province, Nanjing City, Jiangning Science Park Road No. 699 Patentee before: Jiangsu Aosaikang Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 211112 Jiangsu Province, Nanjing City, Jiangning Science Park Road No. 699 Patentee after: Jiangsu Aosaikang Pharmaceutical Co., Ltd. Address before: 211112 Jiangsu Province, Nanjing City, Jiangning Science Park Road No. 699 Patentee before: Jiangsu Aosaikang Pharmaceutical Co., Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20050330 |
|
| CX01 | Expiry of patent term |